MALVERN, Pa. and HAIMEN, China, April 23, 2020 /PRNewswire/ -- Reaction Biology Corporation ("RBC"), a US-based preclinical CRO with offices in Pennsylvania and Germany, and PharmaCore Labs (PCL) Co., Ltd, a Chinese firm with offices in Haimen, China, today announced a joint collaboration agreement in China. Under the terms of the agreement, PCL will supply business support and development personnel to RBC, as well as a staging facility for compound transshipment to the US. RBC will make its full suite of biochemical, cell, and in vivo assay services available to PCL for distribution in China. The arrangement is designed to make it more convenient for Chinese firms to use RBC's services, and also allows RBC to invoice in yuan. https://www.prnewswire.com/news-releases/reaction-biology-and-pharmacore-labs-announce-china-outreach-301045636.html